EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of non‐genetic heterogeneity of BRAF ‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics

Viktoria Zieger, Ellen Woehr, Jasmin Traichel, Tilman Brummer, Roland Zengerle, Sabrina Kartmann, Stefan Zimmermann iD

International Journal of Cancer · 15.07.2026 · 159 (2) · 490-500

DOI: 10.1002/ijc.70453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 15.03.2026. Verfasst von Viktoria Zieger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for MEMS Applications, IMTEK - Department of Microsystems Engineering, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Organoids, Proto-Oncogene Proteins B-raf, Colonic Neoplasms. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für -Forschung, Technologie und Raumfahrt, Deutsches Konsortium für Translationale Krebsforschung, Bundesministerium für Forschung, Technologie und Raumfahrt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patient‐derived organoid (PDO) models are powerful systems for studying tumor biology and drug response. By retaining genetic, histological, and functional characteristics of the original tumor, including intra‐ and interpatient heterogeneity, they provide powerful tools to investigate therapy resistance. While genomic profiling is well established in organoid‐based screening, non‐genetic parameters such as organoid size, seeding density, and morphology remain underexplored, despite their potential to influence functional readouts. Here, we systematically examined how these factors affect proliferation, drug sensitivity, and Wnt responses in a murine colorectal cancer organoid model carrying oncogenic Apc , Braf , and Trp53 mutations. Using our automated Pick‐Flow‐Drop handling platform, we implemented a reproducible plating workflow enabling precise control over organoid selection and screening conditions. We found that higher seeding density and larger organoid size reduced metabolic activity and decreased sensitivity to the MEK inhibitor trametinib. Moreover, distinct morphological subgroups, such as solid and cystic organoids, displayed differential drug responses under growth factor‐deprived conditions, correlating with distinct Wnt‐3a profiles in the culture supernatant. Solid organoids were more trametinib‐sensitive and exhibited higher Wnt‐3a levels, suggesting divergent cell compositions and pathway dependencies. Our findings highlight the functional relevance of non‐genetic variability in organoid cultures and establish a framework to improve reproducibility and biological insight in PDO‐based drug screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsProto-Oncogene Proteins B-rafColonic NeoplasmsAnimalsMiceMutationCell ProliferationHumansWnt Signaling PathwayPyrimidinonesDrug Resistance, NeoplasmPyridones

Stichwörter der Autor:innen

3D cell cultureWnt pathwayautomationcolon organoidsfunctional screeningorganoid heterogeneity

Substanzen

Proto-Oncogene Proteins B-rafPyrimidinonestrametinibPyridones

Autor:innen und Institutionen

  • Laboratory for MEMS Applications, IMTEK - Department of Microsystems Engineering, University of Freiburg, Freiburg, Germany.
  • Hahn-Schickard, Freiburg, Germany.
  • Study Program Molecular and Technical Medicine, Faculty Medical and Life Science, University of Furtwangen, Villingen-Schwenningen, Germany.
  • Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID-Profile: Stefan Zimmermann

Förderung

  • Bundesministerium für -Forschung, Technologie und Raumfahrt
  • Deutsches Konsortium für Translationale Krebsforschung
  • Bundesministerium für Forschung, Technologie und Raumfahrt

Zitieren

APA

Zieger, V., Woehr, E., Traichel, J., Brummer, T., Zengerle, R., Kartmann, S., & Zimmermann, S. (2026). Impact of non‐genetic heterogeneity of BRAF ‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics. International Journal of Cancer, 159(2), 490-500. https://doi.org/10.1002/ijc.70453

Vancouver

Zieger V, Woehr E, Traichel J, Brummer T, Zengerle R, Kartmann S, et al. Impact of non‐genetic heterogeneity of BRAF ‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics. International Journal of Cancer. 2026;159(2):490-500. doi:10.1002/ijc.70453

BibTeX
@article{Zieger2026,
  author = {Zieger, Viktoria and Woehr, Ellen and Traichel, Jasmin and Brummer, Tilman and Zengerle, Roland and Kartmann, Sabrina and Zimmermann, Stefan},
  title = {Impact of non‐genetic heterogeneity of BRAF ‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {2},
  pages = {490--500},
  doi = {10.1002/ijc.70453}
}
Kostenlos starten →